Oncology
Imavolient - 400
Tablet — 400mg
WHO-GMP
Product Overview
Imatinib mesylate 400 mg tablets are an antineoplastic (anti-cancer) agent belonging to the tyrosine kinase inhibitor (TKI) drug class.
Indications
Imatinib mesylate 400 mg tablets are indicated for treating various cancers, including Philadelphia chromosome-positive chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), gastrointestinal stromal tumors (GIST), dermatofibrosarcoma protuberans (DFSP), and myelodysplastic/myeloproliferative diseases.
Dosage Forms & Strength
Available Forms
Tablet
Strength
400mg
Regulatory Approvals
WHO-GMP